- Home
- MCRB vs MOLN Comparison
MCRB vs MOLN Comparison
Compare MCRB & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- MOLN
- Stock Information
- Founded
- MCRB 2010
- MOLN 2004
- Country
- MCRB United States
- MOLN Switzerland
- Employees
- MCRB N/A
- MOLN N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- MOLN
- Sector
- MCRB Health Care
- MOLN
- Exchange
- MCRB Nasdaq
- MOLN Nasdaq
- Market Cap
- MCRB 144.6M
- MOLN 142.6M
- IPO Year
- MCRB 2015
- MOLN 2021
- Fundamental
- Price
- MCRB $20.76
- MOLN $3.74
- Analyst Decision
- MCRB Hold
- MOLN Hold
- Analyst Count
- MCRB 4
- MOLN 1
- Target Price
- MCRB $14.33
- MOLN $4.00
- AVG Volume (30 Days)
- MCRB 227.9K
- MOLN 2.3K
- Earning Date
- MCRB 11-12-2025
- MOLN 11-05-2025
- Dividend Yield
- MCRB N/A
- MOLN N/A
- EPS Growth
- MCRB N/A
- MOLN N/A
- EPS
- MCRB 10.22
- MOLN N/A
- Revenue
- MCRB N/A
- MOLN $856,302.00
- Revenue This Year
- MCRB N/A
- MOLN N/A
- Revenue Next Year
- MCRB N/A
- MOLN $1,000.00
- P/E Ratio
- MCRB $2.05
- MOLN N/A
- Revenue Growth
- MCRB N/A
- MOLN N/A
- 52 Week Low
- MCRB $6.53
- MOLN $3.36
- 52 Week High
- MCRB $24.67
- MOLN $7.60
- Technical
- Relative Strength Index (RSI)
- MCRB 59.57
- MOLN 51.56
- Support Level
- MCRB $19.14
- MOLN $3.68
- Resistance Level
- MCRB $21.97
- MOLN $3.85
- Average True Range (ATR)
- MCRB 1.52
- MOLN 0.09
- MACD
- MCRB 0.22
- MOLN 0.00
- Stochastic Oscillator
- MCRB 78.90
- MOLN 60.71
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.